CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
Oral Testosterone Undecanoatedrug
Likely dose
Oral Testosterone Undecanoate 237 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02921386
NCT02921386Phase 2Completed

A Phase 2 Study of the Effect of Meals With Various Amounts of Fat Given Immediately After Dosing on the Pharmacokinetics of an Oral Testosterone Undecanoate

Clarus Therapeutics, Inc.·interventional·Posted Oct 3, 2016·Updated May 17, 2018

In Brief

A Phase 2 clinical trial evaluating Oral Testosterone Undecanoate for Hypogonadism. Completed, enrolled 18 participants across 2 sites.

Detailed Summary

A Phase 2, open-label, randomized, cross-over, pharmacokinetic study designed to determine the effect of meals of various amounts of fat given immediately prior to dosing on the pharmacokinetics of oral testosterone undecanoate. Approximately 20 hypogonadal subjects will be dosed for a 14 day run-in period. This will be followed by a randomized sequence of five periods over a 6 day confinement period. Subjects will receive a randomly ordered sequence of breakfast meals containing various amounts of fat, fasting, 15 g, 30 g, 45 g and a high fat breakfast consistent Guidance for Industry on Food-Effect Bioavailability and Fed Bioequivalence Studies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypogonadism
CountriesUnited States
CollaboratorsCelerion

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 3, 2016
Enrollment StartOct 1, 2016
Primary CompletionJan 21, 2017
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 9.7 years ago

Interventions

Oral Testosterone Undecanoatedrug

All study participants received Oral TU dose of 237 mg TU twice daily before breakfast and dinner for 14 days and throughout 5 crossover periods